Literature DB >> 7968091

Changes in caudate volume with neuroleptic treatment.

M S Keshavan, W W Bagwell, G L Haas, J A Sweeney, N R Schooler, J W Pettegrew.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 7968091     DOI： 10.1016/s0140-6736(94)90599-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  65 in total

Review 1.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.

Authors:  C Konradi; S Heckers
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

2.  MRI study of caudate nucleus volume and its cognitive correlates in neuroleptic-naive patients with schizotypal personality disorder.

Authors:  James J Levitt; Robert W McCarley; Chandlee C Dickey; Martina M Voglmaier; Margaret A Niznikiewicz; Larry J Seidman; Yoshio Hirayasu; Aleksandra A Ciszewski; Ron Kikinis; Ferenc A Jolesz; Martha E Shenton
Journal:  Am J Psychiatry       Date:  2002-07       Impact factor: 18.112

Review 3.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

Review 4.  [Changes in brain structure caused by neuroleptic medication].

Authors:  H Scherk; P Falkai
Journal:  Nervenarzt       Date:  2004-11       Impact factor: 1.214

Review 5.  Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients.

Authors:  Richard J Beninger; Tyson W Baker; Matthew M Florczynski; Tomek J Banasikowski
Journal:  Neurotox Res       Date:  2010-04-08       Impact factor: 3.911

Review 6.  Neuroimaging correlates of aggression in schizophrenia: an update.

Authors:  Matthew J Hoptman; Daniel Antonius
Journal:  Curr Opin Psychiatry       Date:  2011-03       Impact factor: 4.741

Review 7.  The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia.

Authors:  Lynn E DeLisi
Journal:  Schizophr Bull       Date:  2008-02-08       Impact factor: 9.306

Review 8.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

9.  Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication.

Authors:  Nathan L Hutcheson; David G Clark; Mark S Bolding; David M White; Adrienne C Lahti
Journal:  Psychiatry Res       Date:  2013-10-22       Impact factor: 3.222

10.  Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.

Authors:  Jeffrey R Bishop; James L Reilly; Margret S H Harris; Shitalben R Patel; Rick Kittles; Judith A Badner; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Psychopharmacology (Berl)       Date:  2014-08-07       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.